Adlon Therapeutics L.P. Announces FDA Approval for Adhansia XR™ (methylphenidate HCl) Extended-Release Capsules CII for the Treatment of ADHD - Business Wire

Submitted by Anonymous (not verified) on Fri, 03/01/2019 - 13:30

Adlon Therapeutics L.P. Announces FDA Approval for Adhansia XR™ (methylphenidate HCl) Extended-Release Capsules CII for the Treatment of ADHD  Business WireAdlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved Adhansia XR™ (methylp.